česky english polski

News

: myRisk | 3 new genes in myRisk test

Myriad included additional 3 genes (POLD1, POLE a GREM1) into his multigenic panel myRisk. https://www.myriadpro.com/new-myrisk-genes

: JNCI Oxford Journal - direct comparison of Endopredict & Oncotyped Dx

Head – to Head Breast Cancer study demonstrated that EndoPredict more accurately predicted the recurrence of breast cancer up to 10 years after diagnosis in patients with ER+, HER2- breast cancer than  Oncotype Dx.

http://jnci.oxfordjournals.org/content/108/11/djw149.full.pdf+html

: EndoPredict | Myriad Acquires Sividon Diagnostics

Sividon Acquisition Press Release

: EndoPredict is included in updated ASCO guidelines.

http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.65.2289

: TransATAC

In the TransATAC study 928  patients treated only with endocrine therapy were evaluated with EndoPredict and Oncotype DX.

EndoPredict® outperforms Oncotype DX® in accurately identifying low risk and high risk patients.

ENDO_ATAC_data_01_16_EN.pdf

: San Antonio Breast Cancer Symposium 2015

Lecture: Mitchell Dowsett, December 10,  9.30 AM

EndoPredict (EPclin) score for estimating residual distant recurrence (DR) risk in ER+/HER2- breast cancer patients treated with 5 years adjuvant endocrine therapy alone: Validation and comparison with the Oncotype DX recurrence score (RS)“

http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_444

: Prolaris | October 2015

Myriad Genetics, Inc. today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer.

: ESMO guidelines

September 2015:  In its recently published ”Clinical Practice Guidelines”  the European Society for Medical Oncology (ESMO) advocates the use of the EndoPredict gene expression test for primary diagnosis in breast cancer patients.